Cardiology hypertension

American Journal of Cardiology Figure 13. Sequential changes with intravenous and long-term Propranolol therapy in the same 10 hypertensive patients (31)... 

Current European Society of Cardiology (ESC) guidelines recommend ACE-inhibitor therapy in CAD patients with co-existing indications for ACE-inhibitors, such as hypertension, heart failure, left ventricular dysfunction, prior MI with left ventricular dysfunction, or diabetes (class I, level of evidence A). These guidelines also recommend ACE-inhibitor therapy in all patients with angina and proven coronary disease (class Ila, level of evidence B). 

Puddu GM, Cravero E, Ferrari E, Muscari A, et al. 2007. Gene based therapy for hypertension -Do preclinical data suggest a promising future Cardiology. 108 40-47. 

High risk defer resumption of sexual activity until cardiological assessment and treatment Unstable or refractory angina Increased risk of Ml Uncontrolled hypertension... 

Pulse pressure is another important consideration for you and your physician. Pulse pressure is essentially the difference between the systolic and diastolic pressure readings. Dr. John Cockcroft, an international authority on blood pressure and hypertension at the University of Wales College of Medicine in the United Kingdom, provided a dramatic example of this in an interview featured on Medscape Cardiology, an Internet service for cardiologists and others specializing in heart health. He explained that if you look at the risk of a cardiovascular event such as a heart attack or a stroke in people with a rise of about 20 mm Hg in systolic blood pressure, the risk is not as great as that from a 20 mm Hg rise in pulse pressure. Dr. Cockcroft said that pulse pressure is often a far better predictor of risk than either systolic or diastolic blood pressure alone. 

We already know the benefits that can be derived from lowering levels of what is now called prehypertension to more optimal counts. Results of the study known as TROPHY (TRial Of Preventing Hypertension) were presented at the March 2006 meeting of the American College of Cardiology (ACC). The mean age of patients with prehypertension was 48.5 years half were treated and the other half were not. At the end of the two-year trial, treatment was shown to reduce the risk of progression to hypertension by 66 percent. 

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Gnidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007 28 1462-1536. 

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guide-hues for the management of arterial hypertension. J Hypertens 2003 21(6) 1011-53. 

Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.. American Journal of Cardiology 2002 90 959-963. 

The next frontier is cardiology clinical practice in community pharmacy settings. It is hoped that the progress made in ambulatory practice can be extrapolated into these environments. This possibility has been fueled by demonstration projects where pharmacists receive financial payments for cognitive services. Noteworthy is that some of these initial disease state management efforts (e.g., management of hypertension, lipid disorders, and thrombosis) require practice skills and specialized knowledge in cardiovascular pharmacotherapy. 

In cardiology patients some home-based interventions have been published on the treatment of heart failure patients and heart transplant patients. In our center we also have experience with patients with pulmonary hypertension. 

Rosenthal J, Bahrmann H, Benkert K, et al. Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker. Cardiology 1996 87 409-414. 

Sarnak MJ, et al. Kidney disease as a risk factor for development of cardiovascular disease A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003 42 1050-1065. 

Kreft-Jais, C., Charm, A., DeVries, C., Plouin, P.F., Corvol, P. and Menard, J. (1987) Efficacy and tolerance of spironolactone in essential hypertension. American Journal of Cardiology, 60, 820-825. 

Kolkhof, P., Jilg, V. and Schafer, S. (2007) Pharmacological characterization of a mutant mineralocorticoid receptor responsible for severe, early-onset hypertension. Clinical Research in Cardiology, 96 (Suppl 1). P525. 

Propranolol, a noncardioselective beta-adrenoreceptor blocker (80 to 480 mg/day p.o.) is approved for more indications than any other beta-adrenergic-receptor-blocking drug. The three major areas of use in cardiovascular medicine are the management of CAD, the treatment of hypertension, and the treatment and prophylaxis of supraventricular and ventricular arrhythmias. In addition, propranolol has many other uses and has had a major impact on areas of medicine remote from cardiology and hypertension (see Figures 69, 70, and 83). 

Notes-. ESH/ESC European Society of Hypertension-European Society of Cardiology guidelines, 2003 and 2007 JNC/7 seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, 2003 BHS report of the fourth working party of the British Hypertension Society, 2004 and update of the NICE Hypertension Guidelines, 2006. 

Task Force Members European Society of Hypertension and European Society of Cardiology (2007). J. Hypertens. 25, 1105-1187. 

Kokkinos P, Narayan P, Papademetriou V. Exercise as Hypertension Therapy Cardiology Clinics 2001 19 507-516. 

Kizer, J.R., Hoieggen, A., Alderman, M.H., Kjeldsen, S.E., Dahlof, B. and Devereux, R.B. (2004) Serum uric add and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy the Losartan intervention for endpoint reduction in hypertension (LIFE) study. Journal of the American College of Cardiology, 43,475A. 

Persistent reversal of severe systemic hypertension after prolonged toxic reaction to hydralazine. Cardiology, 60, 251. 

Takeda, R, Ueno, T., Tsutchiya, M. et al. (1975) Sinus arrest following diuretic therapy in a patient with myxedema and hypertension. Cardiology (Basel), 60, 185. 

---